International children's continence society's recommendations for therapeutic intervention in congenital neuropathic bladder and bowel dysfunction in children

Neurourology and Urodynamics

Volumn 31, Issue 5, 2012, Pages 615-620

  Rawashdeh, Y F ^a   Austin, P ^b   Siggaard, C ^a   Bauer, S B ^c   Franco, I ^d   De Jong, T P ^e   Jorgensen, T M ^f  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ST LOUIS CHILDREN S HOSPITAL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f AARHUS UNIVERSITY   (Denmark)

Author keywords

Bladder; Bowel; Neuropathic; Recommendations; Theraputic intervention

Indexed keywords

ANTIBIOTIC AGENT; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; COTRIMOXAZOLE; DARIFENACIN; GENTAMICIN; MUSCARINIC RECEPTOR BLOCKING AGENT; NITROFURANTOIN; OXYBUTYNIN; PROPANTHELINE BROMIDE; PROPIVERINE; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

ACADEMIC ACHIEVEMENT; APPLICATION SITE IRRITATION; BLADDER PRESSURE; BLADDER RECONSTRUCTION; BLADDER SPHINCTER PROSTHESIS; BLURRED VISION; CHILDHOOD DISEASE; CONSTIPATION; CYSTOSTOMY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG STRUCTURE; DRY SKIN; ELECTROSTIMULATION; ENTEROCYSTOPLASTY; FASCIAL SLING; FATIGUE; FEEDBACK SYSTEM; FLUSHING; GASTROENTEROLOGY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INTERNATIONAL CHILDRENS CONTINENCE SOCIETY; INTRAVESICAL ELECTRICAL STIMULATION; MEDICAL DEVICE; MEDICAL SOCIETY; NEUROGENIC BOWEL; NEUROMODULATION; NEUROPATHIC BLADDER; NEUROPATHIC BLADDER DYSFUNCTION; NEUROPATHIC BOWEL DYSFUNCTION; NEUROPATHY; PATIENT COMPLIANCE; PEDIATRIC SURGERY; PEDIATRICIAN; POSTOPERATIVE COMPLICATION; REVIEW; SACRAL NERVE STIMULATION; SIDE EFFECT; SKIN PRURITUS; TRANSCUTANEOUS NEUROMODULATION; TREATMENT INDICATION; URETHRA DILATATION; URINARY CATHETER; URINARY TRACT; URINARY TRACT INFECTION; URINE INCONTINENCE; URODYNAMICS; UROLOGIST; XEROSTOMIA;

AGE FACTORS; CONSENSUS; DIAGNOSTIC TECHNIQUES, UROLOGICAL; EVIDENCE-BASED MEDICINE; FECAL INCONTINENCE; HUMANS; INTESTINES; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER, NEUROGENIC; URINARY INCONTINENCE; UROLOGY;

EID: 84862582915     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.22248     Document Type: Review

References (63)

1. Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: Report from the International Consultation on Incontinence. Curr Opin Urol 2009;19:380-4.
2. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: Their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006;148:565-78. (Pubitemid 43993048)
3. Eglen RM, Choppin A, Watson N. Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol Sci 2001;22:409-14. (Pubitemid 32718632)
4. Hegde SS, Eglen RM. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci 1999;64:419-28. (Pubitemid 29066688)
5. Giramonti KM, Kogan BA, Halpern LF. The effects of anticholinergic drugs on attention span and short-term memory skills in children. Neurourol Urodyn 2008;27:315-8. (Pubitemid 351656403)
6. Buyse G, Waldeck K, Verpoorten C, et al. Intravesical oxybutynin for neurogenic bladder dysfunction: Less systemic side effects due to reduced first pass metabolism. J Urol 1998;160:892-6. (Pubitemid 29479550)
7. Guerra LA, Moher D, Sampson M, et al. Intravesical oxybutynin for children with poorly compliant neurogenic bladder: A systematic review. J Urol 2008;180:1091-7.
8. Franco I, Horowitz M, Grady R, et al. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction. J Urol 2005;173:221-5. (Pubitemid 39627721)
9. Buyse G, Verpoorten C, Vereecken R, et al. Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction. J Urol 1998;160:1084-7. (Pubitemid 29477751)
10. Cartwright PC, Coplen DE, Kogan BA, et al. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. J Urol 2009;182:1548-54.
11. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006;49:644-50. (Pubitemid 43374724)
12. Chapple C, Patel A. Botulinum toxin - New mechanisms, new therapeutic directions? Eur Urol 2006;49:606-8. (Pubitemid 43374719)
13. Game X, Mouracade P, Chartier-Kastler E, et al. Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: A systematic literature review. J Pediatr Urol 2009;5:156-64.
14. Joseph DB, Bauer SB, Colodny AH, et al. Clean, intermittent catheterization of infants with neurogenic bladder. Pediatrics 1989;84:78-82. (Pubitemid 19168041)
15. Schlager TA, Clark M, Anderson S. Effect of a single-use sterile catheter for each void on the frequency of bacteriuria in children with neurogenic bladder on intermittent catheterization for bladder emptying. Pediatrics 2001;108:E71.
16. Schlager TA, Hendley JO, Wilson RA, et al. Correlation of periurethral bacterial flora with bacteriuria and urinary tract infection in children with neurogenic bladder receiving intermittent catheterization. Clin Infect Dis 1999;28:346-50. (Pubitemid 29241225)
17. Guidoni EB, Dalpra VA, Figueiredo PM, et al. E. coli virulence factors in children with neurogenic bladder associated with bacteriuria. Pediatr Nephrol 2006;21:376-81. (Pubitemid 43280353)
18. Schlager TA, Whittam TS, Hendley JO, et al. Expression of virulence factors among Escherichia coli isolated from the periurethra and urine of children with neurogenic bladder on intermittent catheterization. Pediatr Infect Dis J 2000;19:37-41. (Pubitemid 30046614)
19. Mohler JL, Cowen DL, Flanigan RC. Suppression and treatment of urinary tract infection in patients with an intermittently catheterized neurogenic bladder. J Urol 1987;138:336-40. (Pubitemid 17132860)
20. Schlager TA, Anderson S, Trudell J, et al. Nitrofurantoin prophylaxis for bacteriuria and urinary tract infection in children with neurogenic bladder on intermittent catheterization. J Pediatr 1998;132:704-8. (Pubitemid 28194595)
21. Carapetis JR, Jaquiery AL, Buttery JP, et al. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections. Pediatr Infect Dis J 2001;20:240-6. (Pubitemid 32240260)
22. Defoor W, Ferguson D, Mashni S, et al. Safety of gentamicin bladder irrigations in complex urological cases. J Urol 2006;175:1861-4.
23. Wan J, Kozminski M, Wang SC, et al. Intravesical instillation of gentamicin sulfate: In vitro, rat, canine, and human studies. Urology 1994;43:531-6. (Pubitemid 24125996)
24. Stensballe J, Looms D, Nielsen PN, et al. Hydrophilic-coated catheters for intermittent catheterisation reduce urethral micro trauma: A prospective, randomised, participant-blinded, crossover study of three different types of catheters. Eur Urol 2005;48:978-83. (Pubitemid 41641649)
25. Vapnek JM, Maynard FM, Kim J. A prospective randomized trial of the LoFric hydrophilic coated catheter versus conventional plastic catheter for clean intermittent catheterization. J Urol 2003;169:994.
26. Moore KN, Fader M, Getliffe K. Long-term bladder management by intermittent catheterisation in adults and children. Cochrane Database Syst Rev 2007;2:CD006008.
27. Hagerty JA, Richards I, Kaplan WE. Intravesical electrotherapy for neurogenic bladder dysfunction: A 22-year experience. J Urol 2007;178:1680-3. (Pubitemid 47368511)
28. Cheng EY, Richards I, Balcom A, et al. Bladder stimulation therapy improves bladder compliance: Results from a multi-institutional trial. J Urol 1996;156:761-4. (Pubitemid 126444921)
29. Boone TB, Roehrborn CG, Hurt G. Transurethral intravesical electrotherapy for neurogenic bladder dysfunction in children with myelodysplasia: A prospective, randomized clinical trial. J Urol 1992;148:550-4.
30. Guys JM, Haddad M, Planche D, et al. Sacral neuromodulation for neurogenic bladder dysfunction in children. J Urol 2004;172:1673-6. (Pubitemid 39245014)
31. Capitanucci ML, Camanni D, Demelas F, et al. Long-term efficacy of percutaneous tibial nerve stimulation for different types of lower urinary tract dysfunction in children. J Urol 2009;182:2056-61.
32. Johnston JH, Kathel BL. The obstructed neurogenic bladder in the newborn. Br J Urol 1971;43:206.
33. Park JM, McGuire EJ, Koo HP, et al. External urethral sphincter dilation for the management of high risk myelomeningocele: 15-year experience. J Urol 2001;165:2383-8. (Pubitemid 32423935)
34. Miller DC, Bloom DA, McGuire EJ, et al. Temporary perineal urethrostomy for external sphincter dilation in a male patient with high risk myelomeningocele. J Urol 2003;170:1606.
35. Kiddoo DA, Canning DA, Snyder HM III, et al. Urethral dilation as treatment for neurogenic bladder. J Urol 2006;176:1831-34. (Pubitemid 44308480)
36. Wang SC, McGuire EJ, Bloom DA. Urethral dilation in the management of urological complications of myelodysplasia. J Urol 1989;142:1054-55. (Pubitemid 19250766)
37. Lee MW, Greenfield SP. Intractable high-pressure bladder in female infants with spina bifida: Clinical characteristics and use of vesicostomy. Urology 2005;65:568-71. (Pubitemid 40386011)
38. Morrisroe SN, O'Connor RC, Nanigian DK, et al. Vesicostomy revisited: The best treatment for the hostile bladder in myelodysplastic children? BJU Int 2005;96:397-400. (Pubitemid 41097689)
39. Hutcheson JC, Cooper CS, Canning DA, et al. The use of vesicostomy as permanent urinary diversion in the child with myelomeningocele. J Urol 2001;166:2351-3. (Pubitemid 33065306)
40. Nomura S, Ishido T, Tanaka K, et al. Augmentation ileocystoplasty in patients with neurogenic bladder due to spinal cord injury or spina bifida. Spinal Cord 2002;40:30-3. (Pubitemid 34076359)
41. Herschorn S, Hewitt RJ. Patient perspective of long-term outcome of augmentation cystoplasty for neurogenic bladder. Urology 1998;52:672-8. (Pubitemid 28440179)
42. Medel R, Ruarte AC, Herrera M, et al. Urinary continence outcome after augmentation ileocystoplasty as a single surgical procedure in patients with myelodysplasia. J Urol 2002;168:1849-52. (Pubitemid 35034104)
43. Singh G, Thomas DG. Enterocystoplasty in the neuropathic bladder. Neurourol Urodyn 1995;14:5-10.
44. Scales CD, Jr., Wiener JS. Evaluating outcomes of enterocystoplasty in patients with spina bifida: A review of the literature. J Urol 2008;180:2323.
45. Nguyen DH, Bain MA, Salmonson KL, et al. The syndrome of dysuria and hematuria in pediatric urinary reconstruction with stomach. J Urol 1993;150:707-9. (Pubitemid 23213724)
46. Metcalfe PD, Cain MP, Kaefer M, et al. What is the need for additional bladder surgery after bladder augmentation in childhood? J Urol 2006;176:1801.
47. Metcalfe PD, Rink RC. Bladder augmentation: Complications in the pediatric population. Curr Urol Rep 2007;8:152-6. (Pubitemid 46472688)
48. Gros DA, Dodson JL, Lopatin UA, et al. Decreased linear growth associated with intestinal bladder augmentation in children with bladder exstrophy. J Urol 2000;164:917-20. (Pubitemid 30637541)
49. Hensle TW, Gilbert SM. A review of metabolic consequences and long-term complications of enterocystoplasty in children. Curr Urol Rep 2007;8:157-62. (Pubitemid 46472689)
50. Greenwell HR, Nethercliffe JM, Freeman A, et al. Routine surveillance cystoscopy for patients with augmentation and substitute cystoplasty for benign urological conditions: Is it necessary? BJU Int 2009;104:392-5.
51. Kokorowski PJ, Routh JR, Borer JG, et al. Screening for malignancy after augmentation cystoplasty in children with spina bifida: A decision analysis. J Urol 2011;186:37-43.
52. Cartwright PC, Snow BW. Bladder autoaugmentation: Early clinical experience. J Urol 1989;142:505-8. (Pubitemid 19193656)
53. Dik P, Tsachouridis GD, Klijn AJ, et al. Detrusorectomy for neuropathic bladder in patients with spinal dysraphism. J Urol 2003;170:1351-4. (Pubitemid 37108160)
54. Stothers L, Johnson H, Arnold W, et al. Bladder autoaugmentation by vesicomyotomy in the pediatric neurogenic bladder. Urology 1994;44:110-3.
55. Kryger JV, Gonzalez R, Barthold JS. Surgical management of urinary incontinence in children with neurogenic sphincteric incompetence. J Urol 2000;163:256-63.
56. Scott FB, Bradley WE, Timm GW. Treatment of urinary incontinence by implantable prosthetic sphincter. Urology 1973;1:252-9.
57. Catti M, Lortat-Jacob S, Morineau M, et al. Artificial urinary sphincter in children - Voiding or emptying? An evaluation of functional results in 44 patients. J Urol 2008;180:690-3.
58. Gonzalez R, Merino FG, Vaughn M. Long-term results of the artificial urinary sphincter in male patients with neurogenic bladder. J Urol 1995;154:769-70.
59. Kryger JV, Spencer BJ, Fleming P, et al. The outcome of artificial urinary sphincter placement after a mean 15-year follow-up in a paediatric population. BJU Int 1999;83:1026-31. (Pubitemid 29271874)
60. Mattsson S, Gladh G. Tap-water enema for children with myelomeningocele and neurogenic bowel dysfunction Acta Paediatr 2006;95:369-74.
61. Kokoska ER, Keller MS, Weber TR. Outcome of the antegrade colonic enema procedure in children with chronic constipation. Am J Surg 2001;182:625-9. (Pubitemid 34142683)
62. Siddiqui A, Fishman SJ, Bauer SB, et al. Long-term follow-up of patients after antegrade continence enema procedure. J Pediatr Gastroenterol Nutrit 2011;52:574-80.
63. Bond C, Youngson G, MacPherson I, et al. Anal plugs for the management of fecal incontinence in children and adults: A randomized control trial. J Clin Gastroenterol 2007;41:45-53. (Pubitemid 46045671)